Shell Plans To Offload Pakistan Business To Saudi Firm: Report

Energy giant Shell Plc's (NYSE: SHEL) Pakistan unit is reportedly gearing up to transfer its domestic operations as it finalizes a sales agreement with Wafi Energy.

Energy giant Shell Plc’s (NYSE:SHEL) Pakistan unit is reportedly gearing up to transfer its domestic operations as it finalizes a sales agreement with Wafi Energy.

The decision is in line with Shell’s June declaration to exit its 77% stake in the South Asian nation, reported Reuters.

The transaction is expected to be completed by the fourth quarter of 2024.

The Pakistani affiliate has been wrestling with financial challenges aggravated by unfavorable currency shifts and pending payments.

All this is happening as Pakistan navigates through treacherous economic waters, grappling with a looming financial crunch and decelerating economic activity.

The buyer, Wafi Energy, operates as part of Asyad Holding Group, which is rooted in Saudi Arabia and specializes in the fuel retail sector.

The report noted Shell Pakistan’s operations include more than 600 mobility sites, 10 fuel terminals, a lubricant oil blending plant, and a 26% stake in Pak-Arab Pipeline Company Limited.

Price Action: SHEL shares are trading higher by 0.50% at $65.46 on Wednesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Total
0
Shares
Related Posts
Read More

Winmark Announces Multi-Year Resale Partnership With STX; Winmark And STX Will Partner Together To Purchase Quality Used Lacrosse Equipment From Consumers To Advance Circularity And Extend The Life Of Equipment, While Reducing The Barrier Of Entry For…

Agreement recognizes both companies' commitment to circularityand sustainability in communities across North AmericaMINNEAPOLIS, April 18, 2024 /PRNewswire/ -- Winmark Corporation announced today that it has entered into

WINA

Read More

Orchard Therapeutics Announced Long-term Results From An Updated Integrated Analysis Of 39 Patients With Metachromatic Leukodystrophy Treated With Investigational OTL-200 In The Clinical Development Program

Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years of follow-up (median 6.15 years) Composite primary endpoint used

ORTX